Needham & Company LLC Forecasts Strong Price Appreciation for Establishment Labs (NASDAQ:ESTA) Stock

Establishment Labs (NASDAQ:ESTA) had its target price upped by research analysts at Needham & Company LLC from $84.00 to $86.00 in a note issued to investors on Tuesday,Benzinga reports. The firm presently has a “buy” rating on the stock. Needham & Company LLC’s target price would suggest a potential upside of 11.90% from the stock’s current price.

ESTA has been the topic of several other research reports. Weiss Ratings reiterated a “sell (e+)” rating on shares of Establishment Labs in a report on Monday, December 29th. Citigroup boosted their target price on shares of Establishment Labs from $62.00 to $75.00 and gave the company a “neutral” rating in a report on Thursday, December 11th. BTIG Research raised their price target on shares of Establishment Labs from $81.00 to $86.00 and gave the stock a “buy” rating in a report on Wednesday, December 31st. Canaccord Genuity Group upped their price objective on Establishment Labs from $72.00 to $85.00 and gave the company a “buy” rating in a report on Wednesday, December 17th. Finally, JPMorgan Chase & Co. increased their target price on shares of Establishment Labs from $71.00 to $80.00 and gave the stock an “overweight” rating in a research note on Wednesday, December 17th. Six research analysts have rated the stock with a Buy rating, one has given a Hold rating and one has given a Sell rating to the company. Based on data from MarketBeat.com, the stock presently has an average rating of “Moderate Buy” and an average target price of $79.14.

Establishment Labs Price Performance

ESTA traded up $1.89 during trading on Tuesday, reaching $76.85. The company’s stock had a trading volume of 676,329 shares, compared to its average volume of 498,245. The company has a market cap of $2.23 billion, a price-to-earnings ratio of -26.88 and a beta of 0.99. The firm has a fifty day simple moving average of $70.88 and a two-hundred day simple moving average of $57.41. Establishment Labs has a 1 year low of $26.56 and a 1 year high of $78.25. The company has a quick ratio of 2.10, a current ratio of 3.33 and a debt-to-equity ratio of 15.06.

Establishment Labs (NASDAQ:ESTA) last posted its quarterly earnings results on Tuesday, February 24th. The company reported ($0.09) EPS for the quarter, beating the consensus estimate of ($0.22) by $0.13. Establishment Labs had a negative return on equity of 235.45% and a negative net margin of 43.45%.The firm had revenue of $64.62 million during the quarter, compared to analysts’ expectations of $63.80 million. During the same quarter last year, the firm earned ($1.19) earnings per share. The business’s revenue for the quarter was up 45.2% on a year-over-year basis. As a group, analysts anticipate that Establishment Labs will post -2.41 EPS for the current year.

Institutional Trading of Establishment Labs

Institutional investors have recently bought and sold shares of the company. Goldman Sachs Group Inc. raised its stake in Establishment Labs by 117.4% in the 4th quarter. Goldman Sachs Group Inc. now owns 811,536 shares of the company’s stock valued at $59,145,000 after purchasing an additional 438,206 shares during the last quarter. CenterBook Partners LP acquired a new stake in shares of Establishment Labs in the second quarter valued at about $16,204,000. Viking Global Investors LP purchased a new position in shares of Establishment Labs in the second quarter valued at $14,669,000. Bamco Inc. NY boosted its holdings in Establishment Labs by 30.2% in the third quarter. Bamco Inc. NY now owns 1,181,824 shares of the company’s stock valued at $48,443,000 after purchasing an additional 274,287 shares during the last quarter. Finally, Woodson Capital Management LP raised its holdings in Establishment Labs by 113.3% in the third quarter. Woodson Capital Management LP now owns 480,000 shares of the company’s stock valued at $19,675,000 after acquiring an additional 255,000 shares in the last quarter. 72.91% of the stock is currently owned by hedge funds and other institutional investors.

Trending Headlines about Establishment Labs

Here are the key news stories impacting Establishment Labs this week:

• Positive Sentiment: Q4 headline beat — ESTA reported EPS of ($0.09) vs. consensus ($0.22) and revenue of $64.62M vs. $63.8M, with revenue up ~45% year?over?year; the beat and sharp narrowing of losses are the main near?term bullish drivers. Establishment Labs Holdings Inc. (ESTA) Reports Q4 Loss, Tops Revenue Estimates
• Positive Sentiment: FY?2026 revenue guidance slightly above consensus — management guided revenue to $264.0M–$266.0M (vs. consensus ~$263.2M), signaling continued top?line momentum that supports valuation, especially given strong recent growth. Press Release / Guidance
• Neutral Sentiment: Investor materials available — the full Q4 earnings call transcript and the conference call recording give more detail on margin progression, international demand and R&D cadence; useful for gauging whether beats are durable. Establishment Labs Holdings Inc. (ESTA) Q4 2025 Earnings Call Transcript
• Neutral Sentiment: Analyst/industry coverage and previews point to earnings improvement but still highlight execution risk; comparison pieces and previews can help investors benchmark ESTA versus peers. Comparing Establishment Labs (NASDAQ:ESTA) and Pediatrix Medical Group (NYSE:MD) Establishment Labs earnings up next as losses narrow sharply
• Negative Sentiment: Still unprofitable with wide negative margins — Q4 showed a negative net margin (~43.5%) and return on equity is deeply negative; consensus still expects multi?year losses (street EPS forecast for the current fiscal year remains negative), which caps valuation upside until sustained profitability. MarketBeat Q4 results summary
• Negative Sentiment: Balance?sheet/leverage considerations — reported debt?to?equity and other leverage metrics are elevated, which increases sensitivity to slower growth or margin pressure and could limit investor appetite until cash flow turns positive. MarketBeat Financials

About Establishment Labs

Establishment Labs Holdings Inc is a global medical technology company specializing in the design, development and manufacture of silicone gel breast implants for aesthetic and reconstructive surgery. The company’s proprietary portfolio is built around patient-focused safety, customization and innovation, offering solutions intended to enhance surgical outcomes and support clinical traceability.

The company’s flagship products fall under the Motiva® brand, which includes a range of ergonomic and round breast implants featuring SilkSurface® texturing and an embedded Q Inside® Safety microtransponder for unique implant identification.